-
公开(公告)号：US20110045473A1
公开(公告)日：2011-02-24
申请号：US12811511
申请日：2008-12-31
Applicant: Antonin De Fougerolles , Tatiana Novobrantseva , Anna Borodovsky , Akin Akinc , Mark Tracy
Inventor： Antonin De Fougerolles , Tatiana Novobrantseva , Anna Borodovsky , Akin Akinc , Mark Tracy
CPC classification number: G01N33/86 , C12N15/111 , C12N15/1137 , C12N2310/14 , C12Y304/21021 , G01N2333/96447 , Y10T436/143333
Abstract: The invention features a method of identifying therapeutically relevant compositions that include a therapeutic agent and a delivery component by screening for an effect of the agent on the liver of a model subject.
Abstract translation: 本发明的特征在于通过筛选试剂对模型受试者的肝脏的影响来鉴定包括治疗剂和递送组分的治疗相关组合物的方法。
-
32.发明授权公开(公告)号：US07871985B2
公开(公告)日：2011-01-18
申请号：US12331708
申请日：2008-12-10
Applicant: Antonin de Fougerolles , Tatiana Novobrantseva , Akin Akinc
Inventor： Antonin de Fougerolles , Tatiana Novobrantseva , Akin Akinc
CPC classification number: C12N15/1137 , C12N2310/14 , C12N2310/314 , C12N2310/315 , C12N2310/32 , C12N2310/321 , C12N2310/322 , C12N2310/3515 , C12N2310/3521 , C12Y304/21021
Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Factor VII gene.
Abstract translation: 本发明涉及用于抑制因子VII基因表达的双链核糖核酸（dsRNA）。
-
33.发明申请公开(公告)号：US20090264511A1
公开(公告)日：2009-10-22
申请号：US12331708
申请日：2008-12-10
Applicant: Antonin de Fougerolles , Tatiana Novrobrantseva , Akin Akinc
Inventor： Antonin de Fougerolles , Tatiana Novrobrantseva , Akin Akinc
IPC: A61K31/7088 , C07H21/02 , C12N5/00 , C12N15/00 , C12N15/63
CPC classification number: C12N15/1137 , C12N2310/14 , C12N2310/314 , C12N2310/315 , C12N2310/32 , C12N2310/321 , C12N2310/322 , C12N2310/3515 , C12N2310/3521 , C12Y304/21021
Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Factor VII gene.
Abstract translation: 本发明涉及用于抑制因子VII基因表达的双链核糖核酸（dsRNA）。
-
公开(公告)号：US08912316B2
公开(公告)日：2014-12-16
申请号：US13612521
申请日：2012-09-12
Applicant: Antonin De Fougerolles , Pamela Tan , Anna Borodovsky , Tatiana Novobrantseva , Sina Bavari , Kelly Lyn Warfield
Inventor： Antonin De Fougerolles , Pamela Tan , Anna Borodovsky , Tatiana Novobrantseva , Sina Bavari , Kelly Lyn Warfield
IPC: C12Q1/68 , C12N15/113
CPC classification number: C12N15/1137 , C12N15/1138 , C12N2310/113 , C12N2310/14 , C12N2310/17 , C12N2310/315 , C12N2310/321 , C12N2310/3515 , C12N2310/3521
Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the CD45 gene.
Abstract translation: 本发明涉及用于抑制CD45基因表达的双链核糖核酸（dsRNA）。
-
35.发明申请公开(公告)号：US20140200261A1
公开(公告)日：2014-07-17
申请号：US14041011
申请日：2013-09-30
Applicant: Stephen G. Hoge , Tirtha Chakraborty , Joshua P. Frederick , Matthias John , Antonin de Fougerolles
Inventor： Stephen G. Hoge , Tirtha Chakraborty , Joshua P. Frederick , Matthias John , Antonin de Fougerolles
CPC classification number: C07K14/47 , A61K31/7105 , A61K31/711 , A61K38/00 , A61K48/0058 , C12N15/113 , C12N15/85 , C12N2310/141
Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of signal-sensor polynucleotides, primary transcripts and mmRNA molecules.
Abstract translation: 本发明涉及用于制备，制造和治疗性使用信号传感器多核苷酸，初级转录物和mmRNA分子的组合物和方法。
-
Patent Agency Ranking
公开(公告)号：US20140141067A1
公开(公告)日：2014-05-22
申请号：US14107079
申请日：2013-12-16
Applicant: Stephane Bancel , Tirtha Chakraborty , Antonin de Fougerolles , Susan Whoriskey , Ron Weiss
Inventor： Stephane Bancel , Tirtha Chakraborty , Antonin de Fougerolles , Susan Whoriskey , Ron Weiss
IPC: C07K14/47
CPC classification number: A61K48/0066 , A61K9/1271 , A61K9/145 , A61K9/5123 , A61K9/5146 , A61K9/5153 , A61K31/7115 , A61K38/00 , A61K38/17 , A61K38/177 , A61K38/1816 , A61K38/1891 , A61K38/191 , A61K38/193 , A61K38/212 , A61K38/45 , A61K38/4846 , A61K47/543 , A61K48/0033 , A61K48/005 , A61K48/0075 , C07H21/02 , C07K14/005 , C07K14/435 , C07K14/43595 , C07K14/47 , C07K14/4705 , C07K14/4713 , C07K14/4723 , C07K14/4746 , C07K14/475 , C07K14/485 , C07K14/495 , C07K14/505 , C07K14/515 , C07K14/525 , C07K14/535 , C07K14/5418 , C07K14/56 , C07K14/61 , C07K14/62 , C07K14/705 , C07K14/745 , C07K16/00 , C07K16/2863 , C07K16/2887 , C07K16/40 , C12N9/0069 , C12N9/0091 , C12N9/1051 , C12N9/1241 , C12N9/16 , C12N9/2402 , C12N9/2445 , C12N9/6435 , C12N9/6437 , C12N9/644 , C12N9/6443 , C12N9/6451 , C12N9/88 , C12N9/93 , C12N15/11 , C12N15/52 , C12N15/85 , C12N15/87 , C12P13/04 , C12P21/00 , C12P21/005 , C12Y113/12007 , C12Y116/03001 , C12Y207/07012 , C12Y304/21007 , C12Y304/21022 , C12Y304/21027 , C12Y403/02001 , C12Y603/02019 , Y02A50/401 , Y02A50/411 , Y02A50/414 , Y02A50/415 , Y02A50/423 , Y02A50/463 , Y02A50/491
Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of oncology-related polynucleotides, oncology-related primary transcripts and oncology-related mmRNA molecules.
Abstract translation: 本发明涉及用于制备，制造和治疗使用肿瘤学相关多核苷酸，肿瘤学相关的初级转录物和肿瘤相关的mmRNA分子的组合物和方法。
-
公开(公告)号：US20140107189A1
公开(公告)日：2014-04-17
申请号：US14106988
申请日：2013-12-16
Applicant: Stephane Bancel , Tirtha Chakraborty , Antonin de Fougerolles , Susan Whoriskey , Ron Weiss
Inventor： Stephane Bancel , Tirtha Chakraborty , Antonin de Fougerolles , Susan Whoriskey , Ron Weiss
IPC: C07K14/535 , C07K14/505
CPC classification number: A61K48/0066 , A61K9/1271 , A61K9/145 , A61K9/5123 , A61K9/5146 , A61K9/5153 , A61K31/7115 , A61K38/00 , A61K38/17 , A61K38/177 , A61K38/1816 , A61K38/1891 , A61K38/191 , A61K38/193 , A61K38/212 , A61K38/45 , A61K38/4846 , A61K47/543 , A61K48/0033 , A61K48/005 , A61K48/0075 , C07H21/02 , C07K14/005 , C07K14/435 , C07K14/43595 , C07K14/47 , C07K14/4705 , C07K14/4713 , C07K14/4723 , C07K14/4746 , C07K14/475 , C07K14/485 , C07K14/495 , C07K14/505 , C07K14/515 , C07K14/525 , C07K14/535 , C07K14/5418 , C07K14/56 , C07K14/61 , C07K14/62 , C07K14/705 , C07K14/745 , C07K16/00 , C07K16/2863 , C07K16/2887 , C07K16/40 , C12N9/0069 , C12N9/0091 , C12N9/1051 , C12N9/1241 , C12N9/16 , C12N9/2402 , C12N9/2445 , C12N9/6435 , C12N9/6437 , C12N9/644 , C12N9/6443 , C12N9/6451 , C12N9/88 , C12N9/93 , C12N15/11 , C12N15/52 , C12N15/85 , C12N15/87 , C12P13/04 , C12P21/00 , C12P21/005 , C12Y113/12007 , C12Y116/03001 , C12Y207/07012 , C12Y304/21007 , C12Y304/21022 , C12Y304/21027 , C12Y403/02001 , C12Y603/02019 , Y02A50/401 , Y02A50/411 , Y02A50/414 , Y02A50/415 , Y02A50/423 , Y02A50/463 , Y02A50/491
Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of oncology-related polynucleotides, oncology-related primary transcripts and oncology-related mmRNA molecules.
Abstract translation: 本发明涉及用于制备，制造和治疗使用肿瘤学相关多核苷酸，肿瘤学相关的初级转录物和肿瘤相关的mmRNA分子的组合物和方法。
-
公开(公告)号：US08598335B2
公开(公告)日：2013-12-03
申请号：US13614836
申请日：2012-09-13
Applicant: Antonin De Fougerolles , John Diener , Emma Hickman , Gregory Hinkle , Stuart Milstein , Anne-Marie Pulichino , Andrew Griffin Sprague
Inventor： Antonin De Fougerolles , John Diener , Emma Hickman , Gregory Hinkle , Stuart Milstein , Anne-Marie Pulichino , Andrew Griffin Sprague
CPC classification number: C12N15/1138 , A61K31/713 , C12N2310/111 , C12N2310/14 , C12N2310/31 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/344 , C12N2310/351 , C12N2310/3513 , C12N2310/3515 , C12N2310/3517 , C12N2310/3521
Abstract: The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.
-
公开(公告)号：US08344129B2
公开(公告)日：2013-01-01
申请号：US13355879
申请日：2012-01-23
Applicant: Antonin De Fougerolles , John L. Diener , Emma Hickman , Gregory Hinkle , Stuart Milstein , Anne-Marie Pulichino , Andrew Griffin Sprague
Inventor： Antonin De Fougerolles , John L. Diener , Emma Hickman , Gregory Hinkle , Stuart Milstein , Anne-Marie Pulichino , Andrew Griffin Sprague
CPC classification number: C12N15/1138 , A61K31/713 , C12N2310/111 , C12N2310/14 , C12N2310/31 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/344 , C12N2310/351 , C12N2310/3513 , C12N2310/3515 , C12N2310/3517 , C12N2310/3521
Abstract: The present disclosure relates to RNAi agents useful in methods of treating Beta-ENaC-related diseases such as cystic fibrosis, pseudohypoaldosteronism type 1 (PHA1), Liddle's syndrome, hypertension, alkalosis, hypokalemia, and obesity-associated hypertension, using a therapeutically effective amount of a RNAi agent to Beta-ENaC.
-
公开(公告)号：US08293719B2
公开(公告)日：2012-10-23
申请号：US13043228
申请日：2011-03-08
Applicant: Antonin De Fougerolles , Maria Frank-Kamenetsky , Muthiah Manoharan , Kallanthottathil G. Rajeev , Philipp Hadwiger
Inventor： Antonin De Fougerolles , Maria Frank-Kamenetsky , Muthiah Manoharan , Kallanthottathil G. Rajeev , Philipp Hadwiger
CPC classification number: C12N15/1136 , A61K9/0019 , A61K31/7088 , A61K31/712 , A61K31/713 , A61K47/02 , A61K47/10 , A61K47/12 , A61K47/549 , A61K47/551 , A61K47/60 , A61K48/00 , C07K14/475 , C12N2310/14 , C12N2310/3515 , C12N2310/533 , C12N2320/30 , C12N2320/32
Abstract: The features of the present invention relate to compounds, compositions and methods useful for modulating the expression of vascular endothelial growth factor (VEGF), such as by the mechanism of RNA interference (RNAi). The compounds and compositions include iRNA agents that can be unmodified or chemically-modified.
Abstract translation: 本发明的特征涉及用于调节血管内皮生长因子（VEGF）表达的化合物，组合物和方法，例如通过RNA干扰（RNAi）机制。 所述化合物和组合物包括可以未修饰或化学修饰的iRNA试剂。
-
-
-
-
-
-
-
-
-
Search Results
74
records
(took 0.082 seconds)
